chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1. COVID-19 Infection 1. Date of onset of symptoms: 1/10/23 2. Symptoms present on admission: Hypoxemia 3. Date of covid positive test: 1/12/23 4. Vaccination status:  Pfizer x2, No boosters 5. Imaging:  CXR reviewed 6. Oxygen requirements on admission:   4L 7. Current oxygen requirements: room air 8. Medical therapy: Adding Decadron 9. Consultants following:  E-consult placed for ID (Spoke with staff in person). 10. Anticipated special isolation end date: 1/22/23 2. Elevated BNP 1. Appears chronically elevated.  2. Patient appears euvolemic.  3. Acute on Chronic CKD - ACUTE RESOLVED 1. Cr 1.77 on admission 2. 1/13/22 is now 1.37 with IVF 3. Baseline is 1.3-1.4 4. Will stop IVF 4. Diabetes Type II 1. SSI 2. Monitor BG 3. Diabetic Diet as tolerated 5. Elevated Delta Difference Troponin 1 1. Level 18 on 1/12. Will re-check now.  2. Highly likely this is related to deconditioned, dehydrated state s/t COVID-19. 3. Home Eliquis dosing continued. 4. Denies CP 6. Other Chronic Conditions include: Dementia, Stroke, HTN, HLF, CAD, Systolic Heart Failure, OA
DRY MOUTH; TINGLING IN HANDS; HEADACHE; NAUSEA; INCREASED FATIGUE; This spontaneous report received from a patient concerned a 61 year old female. The patient's height, and weight were not reported. The patient's past medical history included thyroidectomy, and concurrent conditions included breast carcinoma, and teeth problems. The patient had no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029, expiry: UNKNOWN) dose was not reported, administered on 16-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 17-MAR-2021, the subject experienced dry mouth. On 17-MAR-2021, the subject experienced tingling in hands. On 17-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced nausea. On 17-MAR-2021, the subject experienced increased fatigue. Laboratory data (dates unspecified) included: Chest X-ray (NR: not provided) normal (units unspecified), and electrocardiogram (NR: not provided) normal (units unspecified). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache, nausea, tingling in hands, increased fatigue, and dry mouth. This report was non-serious.
The symptoms came on around 5pm the same day I received the COVID-19 vaccine, which was at 1:40pm. I also received the flu vaccine (Flucelvax ) at the same time in my right arm. That evening at 5pm, I started having severe symptoms of chills and body pain. I had to take 5 baths throughout the night to get warm enough.  I've been consistently experiencing severe headache, and now odd hot flashes with feeling uncomfortable with sweats, brain fog, full body pain - joint and muscular, neck pain, tingling in legs and feet, nausea, diarrhea, general unwell feeling. I get easily short of breath when walking. My muscles feel like they are about to cramp up after walking. I feel anxious because of these symptoms and been having anxiety attacks. I have had heart palpitations and dental pain (in all of my teeth) and dizziness when ambulating. My lips have been blueish purple or white (which is also why I need to bathe to stay warm, yet our house is at 80 degrees temperature because we do not have air conditioning. But then I subsequently have sweats at the same time.
Fatigue, shooting pains throughout body, headache, low grade fever all started approximately 12 hrs. after receiving vaccination
This spontaneous report as received from a Nurse practitioner refers to unknown number of unspecified patients. On an unknown date, the patients were vaccinated with RECOMBIVAX HB, intramuscular on an accelerated schedule of 4 doses administered on day 0, day 7, day 21, and a booster dose at 12 months after the first dose. No adverse effects reported. Additional information is not expected.
got my first dose eight weeks ago/ it's been two months; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (got my first dose eight weeks ago/ it's been two months) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (got my first dose eight weeks ago/ it's been two months). At the time of the report, PRODUCT DOSE OMISSION ISSUE (got my first dose eight weeks ago/ it's been two months) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported No treatment drugs were reported
About 7 hours after receiving Moderna booster on Dec 01 2021, experienced soreness at injection site which spread to neck and shoulders, followed by body tremors and chills all night.  The following day , experienced severe headaches and bodyaches and a little nausea.  Symptoms subsided on Dec 03, 2021, other than slight soreness at injection site.
Information has been received from a nurse practitioner concerning a 25 year year old female patient with no pertinent medical history, not known drug reactions/allergies who on 01-JUL-2008 was vaccinated intramuscularly with the first GARDASIL vaccine, on 02-SEP-2008 was vaccinated intramuscularly with the second 0.5 mL dose of GARASIL vaccine.  The patient did not have any adverse effects after the first or the second dose.  On an unspecified date, in approximately 2008 the patient was vaccinated intramuscularly with the third 0.5 mL dose of GARDASIL vaccine.  Subsequently the patient developed "achiness" in the injection arm 24 hours after her third dose of GARDASIL vaccine.  The nurse practitioner mentioned that patient had not sustained any injury.  The patient was sent to see an allergist since she had developed hives on approximately 13-NOV-2008, "2 months ago".  The patient's hives were treated with ZYRTEC.  While seeing the allergist the patient mentioned the "achiness" to her arm.  The allergist recommended that the patient saw her primary care provider since he felt it was "a drug reaction".  The patient was seen on 12-JAN-2009 and the nurse practitioner stated she was able to reproduce the discomfort by "pressing down inside elbow and the patient experienced tingling in three of her fingers".  The nurse practitioner mentioned "I did not believe that this is caused by GARDASIL vaccine and there was something else going on".  At the time of reporting, the patient had not recovered.  Additional information has been requested.
no adverse event as of this time wrong dilution of vaccine (1.3 ml vs 1.8 ml) monitor only, no treatment at this time. reported to Health office
pt recvd vax; began feeling pain & discomfort that same day; swelling  & whole arm painful;see by MD;
COVID-19; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient) reported that a female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number and Expiration Date were not reported), via an unspecified route of administration, on 12Jan2021, at a single dose, for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient had the Pfizer COVID-19 vaccine on 12Jan2021 (reported as 21 days ago). Tomorrow (02Feb2021) is her second shot. On 16Jan2021 (16 days before the reporting), the patient got COVID-19. The patient was inquiring for the timeline of second dosage. The outcome of the event was unknown.  Information about lot number and expiration date for the suspect product will be requested in follow-up attempts.
Cough; Sore throat; Diarrhea; Congestion; Runny nose; This is a spontaneous report from a contactable Other Health Professional (nurse, patients wife reported).  A 39-year-old male patient took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Batch/Lot number: EL3248 and Expiry date: Unknown date of Apr2021) via Intramuscular in upper right arm on 11Jan2021(Age at vaccination: 39) as DOSE 2, SINGLE for COVID-19 immunization. The patient's medical history included ongoing anemia, ongoing fibrosis since May2021, family history included mother with Hypothyroidism and Asthma, grand mother with DMII, passed from heart surgery, passed from heart surgery, cardiac and Aunt having hypertension and concomitant medications included Womens Prenatal oral Vitamin since 2010 and still ongoing, Iron 65 mg oral still ongoing for historical asthma and vitamin C 1000 to helps in iron absorption orally and till ongoing. The patient previously took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, Batch/Lot number: EJ1685 and Expiry date: Unknown date of Mar2021) via Intramuscular in right upper arm on 18Dec2021(Age at vaccination: 39) as DOSE 1, 0.3 ML SINGLE for COVID-19 immunization. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine and had not experienced adverse event. On unknown date of July 2021 patient experienced Cough, Sore throat, Diarrhea, Congestion, Runny nose. On 10Jul2021, 11Jul2021, and 14Jul2021 the patient underwent COVID-19 virus test for the results were negative. The outcome of the events was recovering.  Follow-up attempts are completed. No further information is expected.
approx 9mos p/vax pt devel shingles in the same dermatome, & on 20july pt presented to MD w/rash. pt dx w/shingles. treated tylenol, benadryl
Pt recv vax on 2/25/99; on 3/6/99 pt exp swollen lymph nodes behind one ear, 4 days later pt exp rash on trunk
This case was reported by a physician via call center representative and described the occurrence of hepatitis B surface antigen positive in a male patient who received ENGERIX B. Concurrent medical conditions included liver transplant (did not collect dates) and hemodialysis (did not collect dates). On 3rd January 2015, the patient received ENGERIX B. On 5th January 2015, 2 days after receiving ENGERIX B, the patient experienced hepatitis B surface antigen positive. On an unknown, the outcome of the hepatitis B surface antigen positive was not recovered/not resolved. It was unknown if the reporter considered the hepatitis B surface antigen positive to be related to ENGERIX B. Additional information: On 3 January 2015 a patient received a dose of ENGERIX B. Five days before the patient received the dose they had blood work pulled that showed that the patient was HBsAg negative. Forty-eight hours after receiving the ENGERIX B dose the patient had blood work pulled again showing that they were HBsAg positive. They pulled blood work again for a 2nd time on 10 January 2015 and the patient is still showing positive for HBsAg.
Pt vax /w MMR 22DEC90, 27Dec90 experienced N/V/D. 31Dec90 developed a generalized erythematous rash on extremities & trunk, epistaxis & rhinorrhea. Oropharynx was erythematous /w small shallow ulcers. /P 3 days in hosp recovered & D/C
client came in the clinic today to receive his 3rd twinrix.   He stated he was diagnosed with frozen shoulder  from the previous time he was at the clinic.  He is unsure if it was from this visit or the prior visit 12/07/1018.   He also went bowling.  Client has been in therapy for his arm to strengthen and to regain range of motion.   At the previous visit 12/07/2018 he received the influenza vaccine in the left deltoid.
Patient received the vaccine at 1500 and at 1510 she began complaining of numbness to tongue and throat. No shortness of breath, O2 saturation 100%, BP 126/84. Paramedics were on scene assessing another patient she they assessed this patient. She was medically cleared and stable. Patient was released to the care of her mother. She ambulated without difficulty to her car. Her mother drove her home.
Moderna COVID-19 Vaccine EUA Flare-up of GI symptoms, including nausea, starting on 12/31/2020.   Rash at and around injection site- red, raised, itchy, and hot to touch began 7:00 pm 1/1/2021, continuing at present time(1/2/2021 1:00 pm)
This non serious case was received on 24 February 2009 via a search of the VAERS database (reference number 330101). A 52 year old male received FLUZONE SV 2008-2009 (lot number U2757AA) on 16 October 2008. At 3:30 pm post vaccination, the patient had a feeling of a lump in their throat. At 6:30 pm the patient was not feeling well and the lump in their throat caused coughing. The patient had an increase in nausea in the evening and his eyes were burning and had turned red. At 10 pm the patient had an increased in nausea in the evening and his eyes turned blood red. That night he developed a fever, malaise, headache, and weakness. His symptoms continued through 17 October 2008. He felt better on 19 October 2008 and was reported as recovered. No further information was reported. List of Documents held by sender: None.
p/vax pt exp headache. within 24hrs p/vax pt devel rash as well as numbness on side of head & nausea. recovered fr rash day p/onset
rash on both arms; fatigue; headache; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 75-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EN6201) via an unspecified route of administration at arm left on 08Feb2021 16:00 as single dose for COVID-19 immunization. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: El1283, and expiration date not reported) via an unspecified route of administration at arm left on 18Jan2021 17:00 as single dose for COVID-19 immunization. The patient was not diagnosed with COVID-19 prior to vaccination. Medical history included myelitis transverse, drug hypersensitivity unknown if ongoing. Concomitant medication included sertraline (SERTRALINE) taken for an unspecified indication, start and stop date were not reported. On 09Feb2021 the patient experienced rash on both arms, fatigue, headache. The outcome of event rash on both arms was not recovered and rest evets were unknown.  No further details provided.
Flu like symptoms; Sneezing; Watery eyes; Cough; Drainage; Body pain; Agitated; Viciously sick / Feeling sick; Fever; Joint pain; This is a spontaneous case, reported by a non-health professional to Med Communications (reference number: SEQW20-00138) on 12-Mar-2020, concerning a 63-year-old female patient.   The patient's medical history and concomitant medications were not provided.  On 18-Dec-2019, the patient was administered Flucelvax Quadrivalent [influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration, anatomical location, batch number and expiry date: not reported] for influenza prophylaxis. After vaccination, the patient was fine.  On an unspecified date, an unknown amount of time after vaccination, the patient developed flu-like symptoms, sneezing, cough, watery eyes, drainage, fever, body pain and joint pain. It was reported that the patient got viciously sick/ was feeling sick. The patient did not see a physician and did not have any treatment.  At the time of this report, the patent was agitated.The outcome of the events was resolving as it was reported that the patient was feeling better.  The case was assessed as non-serious.  The reporter did not provide causality assessment to Flucelvax Quadrivalent.  Company comment: A 63-year-old female patient developed influenza like illness, sneezing, lacrimation increased, cough, rhinotthoea, pain, agitation, malaise, pyrexia and arthralgia after vaccination with the suspect product Flucelvax Quadrivalent for influenza prophylaxis.  Reportedly, an unknown amount of time after vaccination the patient developed. Chronology needs more clarification. At the time of this report, the patent was agitated. The patient's medical history and concomitant medications were not provided. With information presented, causality is assessed as possibly related for all events.; Sender's Comments: A 63-year-old female patient developed influenza like illness, sneezing, lacrimation increased, cough, rhinotthoea, pain, agitation, malaise, pyrexia and arthralgia after vaccination with the suspect product Flucelvax Quadrivalent for influenza prophylaxis.  Reportedly, an unknown amount of time after vaccination the patient developed. Chronology needs more clarification. At the time of this report, the patent was agitated. The patient's medical history and concomitant medications were not provided. With information presented, causality is assessed as possibly related for all events.
The patient received the immunization on 7/4. I always counsel the patients to let us know if they have any adverse reactions, and the patient came in on 7/6 to show us her arm. Her arm was noticeably swollen down to her elbow. The pharmacist on duty said that it could just be a reaction to the immunization, but recommended that if it got any worse, that she would need to see a doctor. The patient came back in today (7/7), and the swelling had moved a little past her elbow. She said that she had gone to an urgentcare facility, and been diagnosed with cellulitis. The patient was prescribed BACTRIM DS to treat the infection.
flushing of face; chest arms with slight red rash slight itch; chest arms with slight red rash slight itch; This is a spontaneous report from a contactable consumer (patient) via Pfizer Sales Representative. A female patient of unspecified age (age:33, units: unknown) received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 18Dec2020 19:30 at single dose for COVID-19 immunization. The relevant medical history included idiopathic urticaria. Concomitant medications were not reported. After administration of vaccine, the patient experienced flushing of face, chest arms with slight red rash, slight itch in Dec2020. Events took place after use of product. She was given Benadryl and held in Emerge-department for 90 minutes until symptoms were better. The outcome of the events was recovering.  Information about Lot/Batch number has been requested.
This spontaneous report was received from a nurse practitioner concerning her mother of unknown age with. Concurrent medical condition included fibromyalgia. On an unknown date, the patient was vaccinated with ZOSTAVAX (lot number, expiry date, dose and route unspecified). No concomitant medication was reported. On an unknown date, the patient stated that ZOSTAVAX shot caused a flare up of her fibromyalgia. The exact symptoms were not specified. The outcome of the event was unknown. The relatedness of the event of ZOSTAVAX was unknown. Additional information has been requested.
Solid red raised rash to legs and chest. Mother says it is a mild rash. Encouraged mother to take son to doctor to get rash evaluated and to give him some Benadryl as directed on bottle or by MD.
Narrative: Patient reported "feeling sick" x 1 day after first vaccine dose. Patient reported low grade fever, myalgia, headache, and knee pain x 2 days after second vaccine dose. Patient notes continued/ongoing knee pain (less than immediately after vaccine, but still more than baseline/pre-vaccine). The knee pain does improve with diclofenac gel, ibuprofen, and acetaminophen.
Information has been received from a physician concerning a 30 month old male who on 21/NOV/2006 was vaccinated with a single dose of VARIVAX (Oka/Merck) (LOT# 654530/1046F). On 30-Apr-2008 the patient broke out with a full blown case of chicken pox. The patient's symptom persisted. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
swelling behind her teeth; This spontaneous case was reported by a consumer and describes the occurrence of PULPITIS DENTAL (swelling behind her teeth) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 22-Feb-2021, ] prior to the onset of the symptoms, the patient received their second of two planned doses of mRNA-1273  Batch number not provided intramuscularly in the right arm for prophylaxis of COVID-19 infection.   On 22-Feb-2021, the patient experienced PULPITIS DENTAL (swelling behind her teeth).  Action taken with the mRNA-1273 in response to events was not reported   On 22 -FEB-2021, the outcome of events developed swelling behind her teeth was not reported.; Sender's Comments: Based on the current available information which shows a temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
Pt devel fever  of 102 started 2 days p/HBCV & then rash developed on buttocks & spread to legs, trunk & arms; Rash disappeared p/24hrs; Given DPH 2-3times;
The next morning pt & family traveling in car when convuls began lasting 4 mins; pt blue color; taken to ER given DPH - 1 hr;
SOB, wheezing, cough Covid 19 PCR negative on day of vaccine (repeated today)
Severe skin rash- red, itchy , welts , burning and pain . Antihistamine ( Claritin Zyrtec and Benadryl )
tremendous lower back pain shooting down to her toes; little soreness; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (little soreness) and BACK PAIN (tremendous lower back pain shooting down to her toes) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     The patient's past medical history included GERD, Cholesterol and IVP. Concurrent medical conditions included Pollen allergy, Dust allergy, Allergy to animal dander, Penicillin allergy, Shellfish allergy and Blood pressure increased. Concomitant products included ROSUVASTATIN, LANSOPRAZOLE (PREVACID), HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (LOSARTAN HCT), FEXOFENADINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (ALLEGRA D), AMLODIPINE BESILATE, PANTOPRAZOLE and GABAPENTIN.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 05-Jan-2021, the patient experienced INJECTION SITE PAIN (little soreness). On 07-Jan-2021, the patient experienced BACK PAIN (tremendous lower back pain shooting down to her toes). At the time of the report, INJECTION SITE PAIN (little soreness) and BACK PAIN (tremendous lower back pain shooting down to her toes) outcome was unknown.          ; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient up to date of COVID vaccines who had an incidental positive test.  Provider d/c note:  "93 yo F PMH severe protein calorie malnutrition, OA, anemia, HTN, previous SVT s/p ablation admitted for right intertrochanteric femur fracture after mechanical fall after tripping on a rug. Orthopedic surgery consulted and she is now s/p ORIF 7/15.    Course was complicated by acute blood loss anemia and she received a unit of pRBCs for a HgB of 6.6. Course also complicated by leukocytosis, thought to be reactive.    Hospital Course: Patient was continued on AM tramadol and PRN tylenol and Norco for pain. One week of pain medications ordered at discharge.    She was found to have an asymptomatic COVID 19 infection on 7/25.    For her anemia, PO iron was discontinued due to severe constipation. IM B12 given for B12 deficiency.    She was continued on megace for weight loss and poor PO intake. She is following with Dr. as an outpatient.    Ditropan was discontinued secondary to urinary retention, which has resolved at the time on discharge.    Daughter completed family training 7/28 and will stay with patient on discharge to provide support and supervision. "
Pt Received first dose of Gardasil 9 and was light headed and dizzy. Pt stood up, and fell may have hit back of head on wall. Pt never fell all the way to floor, caught on table.